Soligenix Inc. (NASDAQ: SNGX) is advancing a novel therapeutic approach for cutaneous T-cell lymphoma (CTCL) through its development of HyBryte™, also known as synthetic hypericin. CTCL is recognized by clinicians as one of the most difficult cancers to diagnose accurately in its early stages, creating significant challenges for patients and healthcare providers. Within this challenging diagnostic and treatment landscape, HyBryte represents a potential breakthrough as a visible light-activated photodynamic therapy designed specifically for early-stage CTCL.
Unlike traditional ultraviolet-based phototherapies, which can carry long-term safety risks with cumulative exposure, HyBryte is activated by visible light in the red-yellow spectrum. This mechanism allows for targeted treatment of malignant T-cells in the skin while minimizing damage to surrounding healthy tissue. Clinical data reported by Soligenix indicate that HyBryte has demonstrated statistically significant efficacy in reducing CTCL lesions in patients with early-stage disease, addressing a critical gap in rare disease treatment.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company’s Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. The company’s development programs in this business segment also include expansion of synthetic hypericin into psoriasis, as well as first-in-class innate defense regulator technology for inflammatory diseases.
The company’s Public Health Solutions business segment includes development programs for vaccine candidates targeting various threats, incorporating proprietary heat stabilization platform technology known as ThermoVax®. This business segment has been supported with government grants and contract funding from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority. For further information about the company’s broader initiatives, visit https://www.Soligenix.com.
The advancement of HyBryte represents a significant development in oncology treatment, particularly for patients with early-stage CTCL who currently face limited therapeutic options. The therapy’s targeted approach and visible light activation mechanism could potentially reduce the long-term safety concerns associated with traditional phototherapies, offering a more precise treatment modality. As Soligenix progresses toward potential commercialization, the therapy could address substantial unmet needs in the CTCL treatment landscape, providing new hope for patients diagnosed with this challenging form of lymphoma.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Soligenix Advances Novel Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma.